Can Tricuspid Annuloplasty of the Donor Heart Reduce Valve Insufficiency following Cardiac Transplantation with Bicaval Anastomosis?
DOI:
https://doi.org/10.1532/HSF98.20091146Abstract
Background: The aim of this study was to evaluate the degree of tricuspid valve insufficiency after orthotopic cardiac transplantation with bicaval anastomosis and prophylactic donor heart annuloplasty.
Methods: At present, our cardiac transplantation experience includes 478 cases. After January 2002, we included 30 consecutive patients in this study who had undergone orthotopic cardiac transplantation and survived >6 months. The patients were divided into 2 groups: group I, 15 patients who underwent transplantation with prophylactic tricuspid annuloplasty on the donor heart with the De Vega technique; and group II, 15 patients who underwent transplantation without this procedure. Their preoperative clinical characteristics were the same. During the late postoperative follow-up, the degree of tricuspid insufficiency was evaluated by transthoracic Doppler echocardiography and assessed according to the Simpson scale: 0, absent; 1, mild; 2, moderate; and 3, severe. Hemodynamic parameters were evaluated invasively by means of a Swan-Ganz catheter during routine endomyocardial biopsies.
Results: The mean follow-up time was 26.9 ± 5.4 months (range, 12-36 months). In group I, 1 patient (6.6%) died from infection in the 18th month after the operation; the death was not related to the annuloplasty. In group II, 1 death (6.6%) occurred after 10 months because of rejection (P > .05). After the 24-month follow-up, the mean degree of tricuspid insufficiency was 0.4 ± 0.5 in group I and 1.7 ± 0.9 in group II (P < .05). Similarly, the 2 groups were significantly different with respect to the right atrium pressure, which was higher in group II.
Conclusions: Prophylactic tricuspid annuloplasty on the donor heart was able to reduce significantly the degree of valvular insufficiency, even in cardiac transplantation with bicaval anastomosis; however, it did not modify significantly the hemodynamic performance of the allograft during the investigation period. It is very important to extend the observation period and casuistics to verify other benefits that this technique may offer.
References
Anderson CA, Shernan SK, Leacche M, et al. 2004. Severity of intraoperative tricuspid regurgitation predicts poor late survival following cardiac transplantation. Ann Thorac Surg 78:1635-42.nAziz TM, Saad RA, Burgess MI, Campbell CS, Yonan NA. 2002. Clinical significance of tricuspid valve dysfunction after orthotopic heart transplantation. J Heart Lung Transplant 21:1101-8.nBrown NE, Muehlebach GF, Jones P, Gorton ME, Stuart RS, Borkon AM. 2004. Tricuspid annuloplasty significantly reduces early tricuspid regurgitation after biatrial heart transplantation. J Heart Lung Transplant 23:1160-2.nChan MC, Giannetti N, Kato T, et al. 2001. Severe tricuspid regurgitation after heart transplantation. J Heart Lung Transplant 20:709-17.nDe Simone R, Lange R, Sack RU, Mehmanesh H, Hagl S. 1995. Atrioventricular valve insufficiency and atrial geometry after orthotopic heart transplantation. Ann Thorac Surg 60:1686-93.nFiorelli AI, Coelho GH, Oliveira JL Jr, et al. 2009. Endomyocardial biopsy as risk factor in the development of tricuspid insufficiency after heart transplantation. Transplant Proc 41:935-7.nFiorelli AI, Stolf NA, Abreu Filho CA, et al. 2007. Prophylactic donor tricuspid annuloplasty in orthotopic bicaval heart transplantation. Transplant Proc 39:2527-30.nJeevanandam V, Russell H, Mather P, et al. 2004. A one-year comparison of prophylactic donor tricuspid annuloplasty in heart transplantation. Ann Thorac Surg 78:759-66.nJeevanandam V, Russell H, Mather P, Furukawa S, Anderson A, Raman J. 2006. Donor tricuspid annuloplasty during orthotopic heart transplantation: long-term results of a prospective controlled study. Ann Thorac Surg 82:2089-95.nMielniczuk L, Haddad H, Davies RA, Veinot JP. 2005. Tricuspid valve chordal tissue in endomyocardial biopsy specimens of patients with significant tricuspid regurgitation. J Heart Lung Transplant 24:1586-90.nMugge A, Daniel W, Herrmann G, Simon R, Lichtlen PR. 1990. Quantification of tricuspid regurgitation by Doppler color flow mapping after cardiac transplantation. Am J Cardiol 66:884-7.nNguyen V, Cantarovich M, Cecere R, Giannetti N. 2005. Tricuspid regurgitation after cardiac transplantation: How many biopsies are too many? J Heart Lung Transplant 24:S227-31.nSahar G, Stamler A, Erez E, et al. 1997. Etiological factors influencing the development of atrioventricular valve incompetence after heart transplantation. Transplant Proc 29:2675-6.nSarsam MA, Campbell CS, Yonan NA, Deiraniya AK, Rahman AN. 1993. An alternative surgical technique in orthotopic cardiac transplantation. J Card Surg 8:344-9.n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
